Category: clinical study retractions

U Colorado’s former “golden boy” up to 7 retractions

University of Colorado DenverA former graduate student at the University of Colorado Denver has gained three retractions and two expressions of concern (EOC), following an institutional probe into his work. 

Last year, we reported on an investigation by the University of Colorado Denver into the research of Rajendra Kadam, which recommended retracting 10 papers. The report also flagged eight additional papers co-authored by Kadam whose data could not be validated, raising “concerns as to the scientific validity and integrity” of the material. A few months later, we reported on some of the notices — four retractions and an EOC — that had begun to appear for Kadam’s manuscripts.

We’ve since discovered more notices, bringing his total to seven retractions and three EOCs. 

Kadam was once a prominent member in the lab of Uday Kompella, and often referred to by colleagues as the “golden boy,” according to the institution’s report. In 2012, he won a graduate student symposium award from the American Association of Pharmaceutical Scientists.

A University of Colorado Denver spokesperson told Retraction Watch: Continue reading U Colorado’s former “golden boy” up to 7 retractions

Nutrition researcher Chandra, who lost libel suit, charged with health care fraud

R K Chandra
R K Chandra

A nutrition researcher with multiple retractions who unsuccessfully sued the Canadian Broadcasting Corporation (CBC) for libel has been charged with defrauding a state health insurance plan.

The Toronto Star reports that a warrant has been issued for the arrest of Ranjit Kumar Chandra for billing the Ontario Health Insurance Plan for “services that were either not provided or billed inappropriately.” The charges do not appear to be related to his research: Chandra worked once a week as an allergist for the past four years, the Star reports, and the alleged fraud was at least $5,000. Continue reading Nutrition researcher Chandra, who lost libel suit, charged with health care fraud

7th retraction for Ohio researcher who manipulated dozens of figures

Terry Elton, via OSU
Terry Elton

A pharmacology researcher at Ohio State University has added his seventh retraction, four years after a finding of misconduct by the U.S. Office of Integrity (ORI).

An analysis of the work of Terry Elton determined that he had

falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers.

 In 2012, the ORI finding, which resulted in a three-year funding ban (that is now complete), recommended that Elton retract all six papers, one of which had already been retracted at the time of the report. 

Four years later, the last of the six papers flagged by the ORI has finally been retracted by Molecular and Cellular Endocrinology.

Here’s the retraction notice: Continue reading 7th retraction for Ohio researcher who manipulated dozens of figures

A tale of two retraction notices — for the same paper

curentHere’s a strange one: We discovered a paper about an antibiotic-resistant strain of bacteria that bore two retraction notices, and each provided a different reason for retraction. One alleged misconduct; that notice still appears now. The other — which has since disappeared — said the paper was submitted by mistake.

“In vitro effect of boric acid and calcium fructoborate esters against methicillinresistant Staphylococcus aureus strain” was published in the South-Western Journal of Horticulture, Biology and Environment. The full text isn’t available on the journal’s website.

First, here’s the text in the retraction notice that appears when one clicks on the “download full text” link in the table of contents next to the paper: Continue reading A tale of two retraction notices — for the same paper

A retraction cluster? Two papers retracted for overlap with other retractions

molecular biology reportA cluster of papers by different authors has been retracted for sharing text, even though some papers were submitted at the same time.

How is that possible? A spokesperson for Springer told us that they have reason to believe a third-party company may have helped prepare the papers for publication, and in the process might have spread the material around to multiple manuscripts.

The details of the cluster are a bit perplexing, so bear with us. Two of the papers — that were published only months apart — have already been retracted, as we reported in April. Now, two other papers have been retracted from Molecular Biology Reports — and both notices cite the previously retracted papers. The new notices also say that there’s reason to believe that the peer-review process was compromised.

All papers conclude that a certain polymorphism could signal a risk for coronary artery disease among Chinese people.

We’ll start with the retraction notice for “Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study,” which cites the two papers that were retracted previously:

Continue reading A retraction cluster? Two papers retracted for overlap with other retractions

Collateral damage: Paper — and editorial, and author’s response — retracted in one fell swoop

euro jA journal has retracted the results of a clinical trial comparing strategies for bladder tumors after the authors mischaracterized the way patients were assigned to each procedure.

In addition, the journal European Urology has pulled a string of correspondence between author Harry Herr at Memorial Sloan Kettering Cancer Center and an outside expert, who had questioned aspects of the study totally unrelated to the methodology, such as its generalizability.

Here’s the retraction notice for ” Randomized Trial of Narrow-band Versus White-light Cystoscopy for Restaging (Second-look) Transurethral Resection of Bladder Tumors:”  Continue reading Collateral damage: Paper — and editorial, and author’s response — retracted in one fell swoop

Does dose matter? Tumor killer paper thought so, now must retract

Molecular Medicine ReportsAfter questions from a reader, researchers took a second look at their data about the effects of a vitamin A metabolite on tumor cells, and realized their key finding was inaccurate.

They’re now retracting the paper, from Molecular Medicine Reports, because it originally reported that higher concentrations of retinoic acid (RA) were more effective in curbing the proliferation of brain tumor cells. But it seems that the RA dose made less of a difference than they originally believed, according to the retraction notice:

Continue reading Does dose matter? Tumor killer paper thought so, now must retract

UK tribunal orders release of data from controversial chronic fatigue syndrome study

court caseA tribunal in the UK has rejected an appeal by Queen Mary University of London, who sought to reverse a previous order that they release data from a controversial 2011 paper in The Lancet about chronic fatigue syndrome (CFS).

The decision is one in a long series of judgments about the so-called PACE trial, which reported that two treatments — known as cognitive behavioral therapy and graded exercise therapy — helped alleviate the symptoms of the condition. But ever since The Lancet article and follow-up papers have been published, patients and critics have questioned the conclusions and clamored to see the raw data.

The main criticisms: The findings may prompt some to believe chronic fatigue is a mental, not a physical, disorder, and the PACE program could actually be harmful to patients by encouraging too much exercise. These criticisms were recently bolstered by a re-analysis of the evidence by the Agency for Healthcare Research and Quality, which downgraded its original conclusions about the effectiveness of cognitive behavioral therapy and graded exercise therapy.

In March 2014,  Continue reading UK tribunal orders release of data from controversial chronic fatigue syndrome study

Journal blacklists authors for plagiarizing case report about hypersexuality in dementia

Advances in Human BiologyA biology journal has blacklisted authors from publishing their work after finding their case report about a dementia patient with hypersexuality was plagiarized from a previously published report.

The retraction notice, issued by Advances in Human Biology (AIHB) in June, recognizes the case as “scientific misconduct.” The journal launched an investigation after the plagiarism was flagged by the author of the original report, the editor-in-chief of the journal told us. Eventually, the journal retracted the report — and removed it entirely from their website.

Additionally, the journal posted this notice on their site, blacklisting the authors from publishing in AIHB again: Continue reading Journal blacklists authors for plagiarizing case report about hypersexuality in dementia

Judges toss lawsuits by CrossFit gym claiming fraud in $273 million in grants

court caseFederal judges in Ohio have dismissed two lawsuits claiming that university researchers used false results to secure more than $250 million in federal grants.

Both lawsuits, which objected to a study examining the effects of CrossFit-based training, were filed by Mitchell Potterf, the owner of a gym affiliated with CrossFit in Columbus, Ohio. Potterf took issue with a 2013 study by researchers at Ohio State University (OSU) that was conducted at his gym.

Potterf filed one suit against the OSU researchers and a second against the National Strength and Conditioning Association (NCSA). The NSCA publishes the Journal of Strength and Conditioning Research, where a paper about the study appeared. The article, “Crossfit-based high-intensity power training improves maximal aerobic fitness and body composition,” has been cited 15 times, according to Thomson Reuters Web of Science.

The study followed 43 men and women as they completed 10 weeks of CrossFit-based training. In addition to those 43 participants, 11 dropped out before completing the regimen. According to the original paper: Continue reading Judges toss lawsuits by CrossFit gym claiming fraud in $273 million in grants